1. 1OKRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies. (23rd October 2018) Authors: Georgiou, A; Stewart, A; Thavasu, P; Coker, E A; Poelsterl, S; Al-Lazikani, B; Cunningham, D; Whittaker, S; Banerji, U Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 43OUnravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials. (5th March 2018) Authors: Banerji, U; Stewart, A; Coker, E A; Minchom, A; Pölsterl, S; Georgiou, A; Al-Lazikani, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. (17th July 2018) Authors: Basu, B; Krebs, M G; Sundar, R; Wilson, R H; Spicer, J; Jones, R; Brada, M; Talbot, D C; Steele, N; Ingles Garces, A H; Brugger, W; Harrington, E A; Evans, J; Hall, E; Tovey, H; de Oliveira, F M; Carreira, S; Swales, K; Ruddle, R; Raynaud, F I Journal: Annals of oncology Issue: Volume 29:Number 9(2018) Page Start: 1918 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗